Schäfer et al., 2009 - Google Patents
A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretionSchäfer et al., 2009
View HTML- Document ID
- 4449000523803825600
- Author
- Schäfer S
- Müssig K
- Staiger H
- Machicao F
- Stefan N
- Gallwitz B
- Häring H
- Fritsche A
- Publication year
- Publication venue
- Diabetologia
External Links
Snippet
Aims/hypothesis WFS1 type 2 diabetes risk variants appear to be associated with impaired beta cell function, although it is unclear whether insulin secretion is affected directly or secondarily via alteration of insulin sensitivity. We aimed to investigate the effect of a …
- 230000003914 insulin secretion 0 title abstract description 78
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schäfer et al. | A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion | |
Müssig et al. | Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion | |
Schäfer et al. | Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms | |
Shaat et al. | A variant in the transcription factor 7-like 2 (TCF7L2) gene is associated with an increased risk of gestational diabetes mellitus | |
Zhang et al. | Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of US women and men | |
Skov et al. | Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome | |
Jiao et al. | Genome wide association study identifies KCNMA1 contributing to human obesity | |
Tripathy et al. | Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes | |
Haghverdizadeh et al. | ABCC8 genetic variants and risk of diabetes mellitus | |
Prudente et al. | Insulin signaling regulating genes: effect on T2DM and cardiovascular risk | |
Oliveira et al. | Maturity-onset diabetes of the young: from a molecular basis perspective toward the clinical phenotype and proper management | |
Sandholm et al. | Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes | |
Piccini et al. | Clinical and molecular characterization of a novel INS mutation identified in patients with MODY phenotype | |
Chistiakov et al. | The rs11705701 G> A polymorphism of IGF2BP2 is associated with IGF2BP2 mRNA and protein levels in the visceral adipose tissue-a link to type 2 diabetes susceptibility | |
Han et al. | Association of genetic variants of SIRT1 with type 2 diabetes mellitus | |
Dahlgren et al. | Variants of the TCF7L2 gene are associated with beta cell dysfunction and confer an increased risk of type 2 diabetes mellitus in the ULSAM cohort of Swedish elderly men | |
El-Lebedy et al. | Common variants in TCF7L2 and CDKAL1 genes and risk of type 2 diabetes mellitus in Egyptians | |
Müssig et al. | Genetic variants affecting incretin sensitivity and incretin secretion | |
Reis et al. | A polymorphism in the promoter of UCP2 gene modulates lipid levels in patients with type 2 diabetes | |
Kong et al. | Early‐onset type 2 diabetes is associated with genetic variants of β‐cell function in the Chinese Han population | |
Torekov et al. | Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1 | |
Silvia et al. | “H” for heterogeneity in the algorithm for type 2 diabetes management | |
Gomathi et al. | The-866G/A polymorphism in the promoter of the UCP2 gene is associated with risk for type 2 diabetes and with decreased insulin levels | |
Guo et al. | CHRM3 gene variation is associated with decreased acute insulin secretion and increased risk for early-onset type 2 diabetes in Pima Indians | |
Vendrell et al. | β3‐adrenoreceptor gene polymorphism and leptin. Lack of relationship in type 2 diabetic patients |